Rheumatology International

, Volume 27, Issue 11, pp 1071–1077

A pravastatin dose-escalation study in systemic lupus erythematosus

  • Karen H. Costenbader
  • Matthew H. Liang
  • Lori B. Chibnik
  • Juliet Aizer
  • Hannah Kwon
  • Victoria Gall
  • Elizabeth W. Karlson
Original Article

DOI: 10.1007/s00296-007-0341-6

Cite this article as:
Costenbader, K.H., Liang, M.H., Chibnik, L.B. et al. Rheumatol Int (2007) 27: 1071. doi:10.1007/s00296-007-0341-6

Abstract

Statin medications have been suggested for widespread use in patients with systemic lupus erythematosus (SLE). We studied the dose effectiveness and tolerability of pravastatin in SLE. We compared 41 SLE subjects in a two-month open-label dose-titration study of pravastatin to 22 SLE controls. Lipids, ALT, CPK, CRP, adverse effects were assessed. Linear mixed models assessed changes in lipids and CRP, comparing pravastatin subjects to controls. After 1 month of pravastatin 10 mg a day, total cholesterol decreased by 16% (±12.1%) and LDL by 24% (±17%), compared with 1.8% (±7.5%) and 2.6% (±8.6%) decreases in controls (P < 0.001). CRP did not decline. Glucocorticoids appeared to decrease pravastatin effectiveness. Serum CPK increased in one subject. Pravastatin reduced LDL and total cholesterol levels approximately the same degree observed in normal individuals, but the effect appeared blunted in those on modest doses of glucocorticoids and those with higher BMI.

Keywords

Systemic lupus erythematosusAtherosclerosisPreventionStatinCholesterol

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Karen H. Costenbader
    • 1
  • Matthew H. Liang
    • 1
  • Lori B. Chibnik
    • 1
  • Juliet Aizer
    • 2
  • Hannah Kwon
    • 3
  • Victoria Gall
    • 1
  • Elizabeth W. Karlson
    • 1
  1. 1.Division of Rheumatology, Immunology, and Allergy, Section of Clinical SciencesBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA
  2. 2.Division of Rheumatology, Hospital for Special SurgeryWeill Cornell Medical CollegeNew YorkUSA
  3. 3.Department of Anesthesia and Preoperative CareUniversity of California, San FranciscoSan FranciscoUSA